Table 1 Summary of the included studies
Publication Year | First Author | Country | HT | Controls | Total Enrolled | Patient Characteristics | Infection diagnosis | Resistance rates | Treatment duration (days) | Eradication | Eradication rates (ITT)% |
|---|---|---|---|---|---|---|---|---|---|---|---|
2020 | Antonio Mestrovic | Croatia | 71 | 69 (CT) | 140 | Dyspeptic symptoms | SAT, RUT, UBT, HA | CAM > 20%, MET 10.2% | 14 | SAT | 83.1 |
2015 | Jun Heo | Korea | 241 | 209 (CT) | 422 | Dyspeptic symptoms | RUT, UBT or HA | CAM ≥ 20%, MET ≥ 30% | 10 | UBT | 78.8 |
2015 | Jae Jin Hwang | Korea | 144 | 140 (ST) | 284 | Gastritis and/or Peptic Ulcer Disease | UBT, HA, RUT | CAM 37.3%, MET 35.8% | 14 | UBT | 79.2 |
2014 | Vincenzo De Francesco | Italy | 110 | 330 (ST or CT) | 440 | Dyspeptic symptoms | RUT and HA | N/A | 10 (SQ), 14 (HT, CT) | UBT | 82.7 |
2013 | Hossein Sardarian | Iran | 210 | 210 (ST) | 420 | Gastric or Duodenal Erosions | HA and/or RUT | CAM 30%, MET 73.4%, AMOX 6.3%, DR* 21.2% | 14 (HT), 10 (ST) | UBT | 89.5 |
2014 | Dong Hyun Oh | Korea | 90 | 94 (ST) | 184 | Dyspeptic symptoms | RUT or HA | CAM 23.7% AMOX 14.9% | 14 | UBT | 81.1 |
2013 | Javier Molina-Infante | Italy + Spain | 171 | 172 (CT) | 343 | Dyspeptic symptoms | UBT, RUT, HA or Ct | CAM 23.5%, MET 33%, DR 8.8%** | 14 | UBT | 92 |
2015 | Antonio Cuadrado-Lavín | Spain | 120 | 120 (CT) | 300 | Dyspeptic symptoms | UBT, HA or RUT | CAM ~ 14% | 10 | UBT | 90.8 |
2018 | Ayşe Kefeli | Turkey | 170 | 170 (ST) | 340 | Gastritis | HA | CAM 40.2%, MET 45.5% | 14 | UBT | 86.5 |
2017 | Sahoo Ashokkumar | South India | 60 | 60 (ST) | 120 | Gastritis and/or Peptic Ulcer Disease | HA | CAM 33%, MET 78% | 14 (HT), 10 (ST) | HA or RUT | 88.3 |